
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Watson Pharmaceuticals Inc. and Debiopharm S.A. have agreed to market triptorelin pamoate (Trelstar Depot, 3.75 mg, and Trelstar LA, 11.25 mg) within the United States and Canada.






